It is intended to provide novel antiallergic agents usable in preventing and treating allergic diseases such as allergic rhinitis. Thus, antiallergic agents which contain a cyclic and/or chain-form polylactic acid mixture havi ng a degree of condensation of 3 to 20 are provided.
